和譽-B(02256.HK):ABK3376獲國家藥監局IND批准
格隆匯9月24日丨和譽-B(02256.HK)公吿,公司附屬公司上海和譽生物醫藥科技有限公司("和譽醫藥")宣佈,其獨立發現並與上海艾力斯醫藥科技股份有限公司合作研發的新一代EGFR口服小分子抑制劑ABK3376,獲得中國國家藥品監督管理局批准進行首次人體I期臨牀試驗,用於治療伴有EGFR-C797S耐藥突變的非小細胞肺癌。
此為公司刊發的自願公吿。集團無法保證ABK3376最終將成功獲批上市。公司股東及潛在投資者於買賣公司股份時務請審慎行事。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.